Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Single-Payer Healthcare
  • Federal Workers’ Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

WHAT'S NEW

  • Single-Payer Healthcare
  • Federal Workers' Medical Records
  • TrumpRx
  • Pharmacy Discount Coupons
  • Hantavirus

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Jul 29 2016

Full Issue

U.S. Forms Trans-Atlantic Partnership In Effort To Stem Tide Of Superbugs

The Department of Health and Human Services will invest $250 million into CARB-X, the initiative to foster development of drugs that will target antibiotic-resistant bacteria.

The Washington Post: Major Global Partnership To Speed Antibiotic Development Launched

U.S. and British officials announced an ambitious collaboration Thursday designed to accelerate the discovery and development of new antibiotics in the fight against one of the modern era’s greatest health threats: antibiotic resistance. CARB-X, for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, will create one of the world’s largest public-private partnerships focused on preclinical discovery and development of new antimicrobial products. (Sun, 7/28)

The Wall Street Journal: U.S. To Form International Partnership To Fight ‘Superbugs’

The U.S. Department of Health and Human Services is expected to invest $250 million over the next five years to the public-private initiative, which will be known as CARB-X, for Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator. The venture, which has grown out of a 2015 Obama administration initiative, will focus on providing monetary help to small companies and laboratories that are in the earliest stages of developing new drugs, vaccines or medical devices to combat such microbes. (Burton, 7/28)

Stat: With Superbug Scourge Looming, Global Group Bets On Biotechs To Turn The Tide

“We’re not looking for just the next iteration on an existing class [of drugs]. We’re looking for substantial improvement and novel approaches,” said Joe Larsen, acting deputy director of BARDA, the division of the US Department of Health and Human Services that’s providing funds for the project. (Garde and Silverman, 7/28)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, May 8
  • Thursday, May 7
  • Wednesday, May 6
  • Tuesday, May 5
  • Monday, May 4
  • Friday, May 1
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF